
Avadel Pharma (AVDL) Stock Forecast & Price Target
Avadel Pharma (AVDL) Analyst Ratings
Bulls say
Avadel Pharmaceuticals PLC is positioned for significant growth through its flagship product, LUMRYZ, which could achieve over $500 million in peak sales due to its convenient once-nightly dosing compared to existing sodium oxybate treatments. The company has recently reached cash flow positivity, fueled by the robust sales growth of LUMRYZ since its approval in 2023, and has established a strong patient base that is showing an increasing preference for this product. Moreover, Avadel's strategic transaction terms and ongoing pivotal trials in indications like idiopathic hypersomnia further enhance its potential for expansion and financial success in the pharmaceutical market.
Bears say
Avadel Pharmaceuticals faces significant risks that contribute to a negative outlook on its stock, particularly regarding its flagship product, LUMRYZ. Key concerns include the potential for slower market uptake due to impending generic competition, which may lead to greater pricing pressures and hinder sales projections. Additionally, the company's prospects are further complicated by litigation risks, challenges in demonstrating the efficacy of LUMRYZ in ongoing clinical trials, and possible delays in commercialization efforts for new indications.
This aggregate rating is based on analysts' research of Avadel Pharma and is not a guaranteed prediction by Public.com or investment advice.
Avadel Pharma (AVDL) Analyst Forecast & Price Prediction
Start investing in Avadel Pharma (AVDL)
Order type
Buy in
Order amount
Est. shares
0 shares